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While signal transducers and activators of transcription (STATs) were originally discovered as intracellular
effectors of normal signaling by cytokines, increasing evidence also points to a role for STAT transcription
factors in oncogenesis. Previous studies have demonstrated that one STAT family member, Stat3, possesses
constitutively elevated tyrosine phosphorylation and DNA-binding activity in fibroblasts stably transformed by
the Src oncoprotein. To determine if this Stat3 activation by Src could induce Stat3-mediated gene expression,
luciferase reporter constructs based on synthetic and authentic promoters were transfected into NIH 3T3 cells.
Activation of endogenous cellular Stat3 by the Src oncoprotein induced gene expression through a Stat3-
specific binding element (TTCCCGAA) of the C-reactive protein gene promoter. A naturally occurring splice
variant of human Stat3 protein, Stat3b, with a deletion in the C-terminal transactivation domain abolished
this gene induction in a dominant negative manner. Expression of Stat3b did not have any effect on a reporter
construct based on the c-fos serum response element, which is not dependent on Stat3 signaling, indicating that
Stat3b does not nonspecifically inhibit other signaling pathways or Src function. Transfection of vectors
expressing Stat3b together with Src blocked cell transformation by Src as measured in a quantitative focus
formation assay using NIH 3T3 cells. By contrast, Stat3b had a much less pronounced effect on focus formation
induced by the Ras oncoprotein, which does not activate Stat3 signaling. In addition, three independent clones
of NIH 3T3 cells stably overexpressing Stat3b were generated and characterized, demonstrating that Stat3b
overexpression does not have a toxic effect on cell viability. These Stat3b-overexpressing clones were shown to
be deficient in Stat3-mediated signaling and refractory to Src-induced cell transformation. We conclude that
Stat3 activation by the Src oncoprotein leads to specific gene regulation and that Stat3 is one of the critical
signaling pathways involved in Src oncogenesis. Our findings provide evidence that oncogenesis-associated
activation of Stat3 signaling is part of the process of malignant transformation.
Signal transducers and activators of transcription (STATs)
are latent cytoplasmic transcription factors that were first iden-
tified as mediators of cellular responses to interferons (re-
viewed in references 12, 16 and 35). Signaling induced by the
interaction of interferons and other cytokines with their cog-
nate receptors is initiated by a cascade of events, including
receptor aggregation and activation of Janus protein tyrosine
kinases (JAKs) associated with the receptors. Subsequently,
STAT proteins are recruited to the receptor-JAK complexes
and activated by tyrosine phosphorylation, which promotes the
formation of homodimers or heterodimers of STAT family
members. Activated STATs, in turn, translocate to the nucleus
and bind to specific DNA response elements that regulate gene
expression. There are at least seven genes in the mammalian
genome known to encode different STAT family members,
which are activated in various combinations in response to
stimulation by numerous cytokines (12, 16, 35).
It has become evident that, in addition to cytokines, mito-
genic growth factors, such as platelet-derived growth factor
and epidermal growth factor, also induce STAT signaling, par-
ticularly Stat1, Stat3, and Stat5 (21, 35). An emerging concept
is that normal signaling by STAT proteins is involved in control
of diverse biological processes regulated by cytokines and
growth factors, including cell differentiation, proliferation, de-
velopment, and apoptosis (2, 4, 10, 13, 19, 20, 22, 23, 26, 29, 31,
37, 39, 40, 50). Increasingly, evidence that indicates an associ-
ation between abnormal activation of STAT signaling and on-
cogenesis has also been accumulating. For example, we and
other investigators have demonstrated constitutive activation
of Stat1, Stat3, Stat5, and Stat6 in cells transformed by Src,
Abl, and various other oncoproteins and tumor viruses (7, 8,
11, 14, 24, 25, 47, 51). In the context of human cancer, there is
a high frequency of activation of Stat1, Stat3, and Stat5 in
breast carcinoma cells (14, 32, 42) and in lymphoid malignan-
cies, including lymphomas and leukemias (15, 43, 49). Al-
though these findings suggest a role for STAT signaling in cell
transformation as well as in human cancer, direct evidence for
the obligatory requirement of STAT signaling in oncogenesis
has not been reported previously.
Because transformation of mammalian fibroblasts by viral
Src (v-Src) specifically induces constitutive activation of one
STAT family member, Stat3, this system is ideal for investigat-
ing the role of Stat3 signaling in oncogenesis (7, 47). The
embryonic lethality of targeted disruption of the Stat3 gene
(39), however, precludes generation of viable Stat3-deficient
mouse models for these studies. An alternative approach for
disrupting Stat3 function is to make use of Stat3 dominant
negative proteins that interfere with Stat3 signaling. One such
variant of Stat3, known as Stat3b, has been shown to block
Stat3 function in response to interleukin 5 (IL-5) stimulation
(5). Stat3b is a naturally occurring splice variant with a dele-
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tion in the C-terminal portion that harbors the transcriptional
activation domain and the Ser-727 residue, phosphorylation of
which is required for efficient transcriptional activation (44,
45). As a result of this C-terminal deletion, dimers formed with
human Stat3b lack transcriptional activity (5). In some studies,
however, mouse Stat3b has been shown to activate the pro-
moters of certain genes in a cell type-dependent manner (33,
34), suggesting that the dominant negative effect of Stat3b may
be cell type specific.
To investigate Stat3-mediated gene regulation by v-Src and
the role of Stat3 in oncogenesis, we disrupted Stat3 signaling
by using human Stat3b. We report that in NIH 3T3 fibroblasts
transiently expressing luciferase reporter constructs, v-Src in-
duced Stat3-specific transcriptional activation. As a potent dom-
inant negative modulator of Stat3-mediated signaling, Stat3b
effectively blocked Stat3-specific gene expression induced by
v-Src in these cells. Furthermore, cotransfection of expression
vectors encoding Stat3b and v-Src suppressed cell transforma-
tion of NIH 3T3 fibroblasts, and stable cell lines overexpressing
Stat3b were found to be resistant to transformation by v-Src.
Our findings establish that activation of Stat3 by v-Src induces
specific gene regulation and provide evidence for the require-
ment of Stat3 signaling in cell transformation by the Src on-
coprotein.
MATERIALS AND METHODS
Construction of plasmids. An annealed oligonucleotide corresponding to the
235 to 111 region (relative to the transcriptional start site at 11) of the herpes
simplex virus thymidine kinase (TK) promoter was cloned between the KpnI and
BglII sites of the basic luciferase reporter pLuc (pGL2; Promega) to construct
pLucTK (see Fig. 1 for structures of constructs). The Stat3 reporter pLucTKS3
was constructed from pLucTK by inserting seven copies of an annealed oligo-
nucleotide corresponding to a Stat3-specific binding site from the human C-re-
active protein (CRP) gene (48), called the CRP acute-phase response element
(cAPRE) (nucleotides 2123 to 285), into the SmaI site upstream of the TK
minimal promoter. Another reporter, pLucTKSIE, contains two copies of an
annealed oligonucleotide corresponding to a high-affinity mutant of the c-fos
sis-inducible element (hSIE [mutant m67]) (41) inserted into the SmaI site of
pLucTK. To construct pLucCRP, the authentic CRP promoter (nucleotides
2123 to 13) was excised from plasmid 2123/13CRP-CAT (48) (a generous gift
from D. Samols) by BamHI-XhoI restriction digestion, blunt-ended with Klenow,
and inserted into the SmaI site of pLuc. The human Stat3b expression vector
pSG5hStat3b is driven by the simian virus 40 promoter contained in pSG5
(Stratagene) and has been previously described (5). The Stat3 expression vector
pVRStat3 was constructed by excising the mouse Stat3 cDNA from pBSStat3 by
EcoRI and DraIII digestion, blunt-ending with T4 DNA polymerase, and cloning
into a vector driven by the cytomegalovirus immediate early gene promoter (2a,
50). The reporter pLucSRE, which contains a serum response element (SRE) in
the context of the c-fos promoter driving luciferase expression, as well as the
N17-Ras and NT-Raf vectors have been described previously (30, 46). Expres-
sion vectors for v-Src, pMvSrc (17), and oncogenically activated c-H-Ras have
been described previously (28).
Cell culture and transfections. NIH 3T3 fibroblasts were grown in Dulbecco’s
modified Eagle’s medium (DMEM) containing 5% iron-supplemented bovine
calf serum (BCS). Transfections were carried out by the standard calcium phos-
phate method (9). NIH 3T3 fibroblasts were seeded at 5 3 105 cells/100-mm-
diameter plate in DMEM plus 5% BCS at 18 to 24 h prior to transfection. Total
DNA for transfections was typically 20 mg per plate, including 4 mg of luciferase
reporter construct (pLucTK, pLucTKS3, pLucCRP, pLucTKSIE, or pLucSRE),
0.2 mg of b-galactosidase (b-Gal) internal control vector, and the amounts of
expression vector indicated in Results. Transfection was terminated 15 h later by
aspirating the medium, washing the cells with 13 phosphate-buffered saline
(PBS), and adding fresh DMEM. Where gamma interferon (IFN-g) was present,
it was added 5 h prior to harvest of transfected cells.
Preparation of cytosolic and nuclear extracts. For transient expression assays,
cytosolic extracts were prepared from cells at 48 h posttransfection. Briefly, after
two washes with 13 PBS and equilibration for 5 min with 0.5 ml of PBS–0.5 mM
EDTA, cells were scraped off of the dishes and the cell pellet was obtained by
centrifugation (4,500 3 g, 2 min, 4°C). Cells were resuspended in 0.4 ml of
low-salt HEPES buffer (10 mM HEPES [pH 7.8], 10 mM KCl, 0.1 mM EGTA,
0.1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, and 1 mM dithiothreitol)
for 15 min, lysed by the addition of 20 ml of 10% Nonidet P-40, and centrifuged
(10,000 3 g, 30 s, 4°C) to obtain the cytosolic supernatant, which was used for
luciferase assays (Promega) with a luminometer and for b-Gal activity detection
by colorimetric assay at A570. As an internal control for transfection efficiency,
results were normalized to b-Gal activity. For electrophoretic mobility shift
assays (EMSA), nuclear extracts were prepared from transiently transfected NIH
3T3 cells and volumes containing equal amounts of total protein were incubated
with 32P-labeled hSIE oligonucleotide probe, as previously reported (47). Super-
shift assays were performed by using rabbit polyclonal antibodies against the
C-terminal amino acid residues (750 to 769) of full-length Stat3 that are absent
in Stat3b (Santa Cruz Biotechnology).
Western blot analysis. Whole-cell lysates were prepared in boiling sodium
dodecyl sulfate (SDS) sample buffer in order to extract total Stat3 proteins from
the cytoplasm and nucleus. Equivalent amounts of total cellular protein were
electrophoresed on an SDS–7.5% polyacrylamide gel and transferred to a nitro-
cellulose membrane. Probing of nitrocellulose membranes with primary antibod-
ies and detection of horseradish peroxidase-conjugated secondary antibodies by
enhanced chemiluminesence (Amersham) were performed as previously de-
scribed (14, 47). Probes used were rabbit polyclonal antibodies against the Stat3
C-terminal amino acids that are specific for full-length Stat3 (Santa Cruz Bio-
technology) or mouse monoclonal antibody against the Stat3 N-terminal amino
acid residues (1 to 178) that recognizes both full-length Stat3 and Stat3b (Trans-
duction Laboratories).
Focus formation assays. NIH 3T3 fibroblasts were transfected as described
above and then harvested by trypsinization at 48 h posttransfection. Cytosolic
extracts were prepared from 25% of the transfected cells to measure b-Gal
activity, which was used for determination of transfection efficiency. The remain-
ing 75% of the cells were seeded into new dishes and fed 13 DMEM every 3
days. Foci were counted at 16 or 21 days posttransfection by using phase-contrast
microscopy.
RESULTS
Stat3-mediated gene regulation is induced by Src. We pre-
viously demonstrated that Stat3 is constitutively activated in
Src-transformed fibroblasts, as measured by enhanced tyrosine
phosphorylation and DNA-binding activity of Stat3 (47). To
determine whether Stat3 activation by Src could lead to
regulation of gene expression, we transiently transfected NIH
3T3 cells with v-Src expression vector and a reporter construct,
pLucTKS3 (Fig. 1B), containing multimerized Stat3-specific
binding sites inserted upstream of a TK minimal promoter.
This Stat3-specific binding site, which is derived from the hu-
man CRP gene and is called cAPRE here, contains the core
sequence TTCCCGAA (36, 48). Assays for luciferase reporter
gene expression (Fig. 2A) show dose-dependent gene induc-
tion, up to 15-fold over basal levels, mediated through activa-
tion of endogenous cellular Stat3 by increasing amounts of
transfected v-Src expression vector. To confirm that this gene
induction is dependent on Stat3, we used an expression vector
encoding the Stat3 splice variant, Stat3b (Fig. 1A) (5), to dis-
rupt Stat3 signaling. Figure 2B shows that induction of pLucTKS3
by v-Src requires the presence of cAPRE and is reduced to
basal levels by cotransfection with Stat3b expression vector. To
further characterize the dominant negative properties of Stat3b,
Fig. 3A shows that increasing amounts of transfected Stat3b
vector results in dose-dependent inhibition of Src-induced
Stat3 reporter expression. In contrast to Stat3b, cotransfection
of an expression vector encoding full-length Stat3 results in
increased levels of gene induction over that observed with
v-Src alone (Fig. 3B). Together, these results establish that
activation of Stat3 by v-Src leads to Stat3-mediated gene reg-
ulation.
Specificity of Stat3-mediated gene regulation. An authentic
promoter construct, pLucCRP (Fig. 1B), harboring cAPRE
embedded in the natural context of the CRP gene’s promoter
(48), was used to confirm the results obtained with the chi-
meric pLucTKS3 reporter. Figure 4A shows that v-Src induces
expression from pLucCRP and that Stat3b functions as a dom-
inant negative modulator of transcription from this promoter,
in agreement with the results presented above. As a control,
Fig. 4B shows that Stat3b overexpression has no effect on the
ability of v-Src to induce another reporter construct, pLucSRE
(Fig. 1B), containing the c-fos SRE that is dependent on Ras
and Raf-1 signaling for activation (46). In similar experiments
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with 20 mg of Stat3b vector and 200 ng of v-Src vector, the
same conditions used in subsequent focus formation assays
(see below), there was no effect of Stat3b on the ability of Src
to induce pLucSRE expression (data not shown). These results
demonstrate that Stat3b acts through Stat3-binding sites and
that Stat3b overexpression does not nonspecifically inhibit v-
Src function or Stat3-independent signaling pathways leading
to SRE induction.
To further characterize the specificity of Src-induced STAT
signaling and Stat3b function, we used a reporter construct
based on the c-fos SIE inserted upstream of the TK promoter.
This reporter, pLucTKSIE (Fig. 1B), contains a high-affinity
mutant of the SIE (hSIE) that binds both Stat1 and Stat3 (41,
47). Figure 5A shows that expression from pLucTKSIE was
induced by v-Src, which activates Stat3 but not Stat1 (47), and
to a lesser extent by IFN-g, which activates Stat1 but not Stat3
(4, 47). In both cases, gene induction was blocked by expres-
sion of Stat3b, indicating that Stat3b can disrupt Stat1 and
Stat3 signaling. For comparison of the specificity of the various
reporter constructs for Stat1 and Stat3, pLucTKS3, pLucCRP,
and pLucTKSIE were activated by either v-Src or IFN-g. Re-
sults shown in Fig. 5B demonstrate that the pLucTKS3 and
pLucCRP constructs, both of which harbor cAPRE, are in-
duced specifically by v-Src and not by IFN-g. This finding
confirms that cAPRE responds only to Stat3 signaling and not
to Stat1 signaling. Together, our results demonstrate that ac-
tivation of endogenous cellular Stat3 signaling by v-Src leads to
Stat3-specific induction of gene expression, which is disrupted
in a dominant-negative manner by Stat3b.
Induction of Stat3 and Stat3b DNA-binding activity by Src.
Because Stat3b retains an intact DNA-binding domain as well
as the SH2 domain and tyrosine required for dimerization,
activation of Stat3b by v-Src is predicted to induce dimeriza-
tion and DNA binding. To measure DNA-binding activities,
we prepared nuclear extracts from transiently transfected NIH
3T3 cells and performed EMSA with the 32P-labeled SIE
probe that binds both Stat1 and Stat3 with high affinity. Con-
sistent with earlier studies of fibroblasts stably transformed by
v-Src (47), Fig. 6A (lanes 1, 2, and 11 to 15) shows that specific
DNA-binding activity of endogenous Stat3, but not Stat1, is
induced in an Src-dependent manner in transiently transfected
NIH 3T3 cells. Moreover, the Src-induced levels of specific
DNA-binding activity detected in transiently transfected cells
overexpressing Stat3 or Stat3b are greater than 10-fold higher
than that of cells containing only endogenous Stat3 (Fig. 6A,
lanes 3 to 10). As reported earlier (5, 34), Stat3b appears to
FIG. 1. Schematic representations of Stat3 proteins and reporter constructs.
(A) Full-length Stat3 and Stat3b, which is a naturally occurring splice variant
with a deletion in the C-terminal transactivation domain, are diagrammed with
various protein domains and the major sites of phosphorylation shown. (B) The
reporter construct pLucTK contains only the TK minimal promoter driving
luciferase (LUC) gene expression, while pLucTKS3 has seven copies of a Stat3-
specific binding site (cAPRE) from the CRP gene inserted upstream of the TK
minimal promoter. pLucCRP contains an authentic CRP promoter fragment
driving expression of the luciferase gene. pLucTKSIE has two copies of a high-
affinity mutant (hSIE) of the c-fos SIE inserted upstream of the TK minimal
promoter, whereas pLucSRE contains a c-fos promoter fragment harboring the
SRE inserted upstream of TK promoter sequences. Not shown is the basic pLuc
backbone vector, which contains the luciferase gene without promoter sequences
cloned in pUC19. See Materials and Methods for additional details of constructs.
FIG. 2. Induction of Stat3-specific gene expression by v-Src. NIH 3T3 cells
were transiently transfected with the indicated plasmid vectors, and luciferase
reporter activity in cytosolic extracts was measured as light emission, with a lu-
minometer. (A) Cells were transfected with pLucTK reporter alone or pLucTKS3
reporter plus increasing concentrations of the v-Src expression vector, pMvsrc.
(B) Cells were transfected with pLucTK or pLucTKS3 reporters in the presence
or absence of vectors encoding v-Src, Stat3b, or both. Values shown in each pa-
nel are means plus standard deviations of at least four independent transfections,
each performed in triplicate. For each transfection, luciferase activity was nor-
malized to transfection efficiency, with b-Gal activity as an internal control.
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have a higher basal level of DNA-binding activity than does
Stat3 in the absence of any external stimulus.
Previous studies of cells stimulated with IL-5 demonstrated
that Stat3b can form homodimers, which migrate more slowly
in EMSA than Stat3 homodimers, as well as heterodimers with
Stat3, which exhibit an intermediate degree of migration (5).
By supershift analysis with an antibody that recognizes a C-
terminal epitope present in full-length Stat3 but not in Stat3b,
we confirmed that activation of Stat3 or Stat3b by v-Src in-
duces mostly homodimers when either one is overexpressed
alone (Fig. 6B, lanes 1 to 10) and predominantly Stat3-Stat3b
heterodimers when both proteins are overexpressed together
(lanes 11 to 16). Combined with our results presented above,
these data suggest that Stat3b disrupts Stat3-specific gene reg-
ulation by binding to Stat3 response elements as either a ho-
modimer or a heterodimer and preventing transcriptional ac-
tivation.
Cotransfection of Stat3b vector blocks Src transformation.
To investigate the role of Stat3 signaling in cell transformation,
we tested the effect of Stat3b on transformation of NIH 3T3
cells by v-Src. As a sensitive and quantitative measure of
cell transformation by v-Src, we used a focus formation assay,
which in the case of v-Src correlates very well with growth in
soft agar and tumorigenesis (18). Focus formation assays were
performed by using cells transfected with expression vectors
for v-Src alone or v-Src together with Stat3b (Fig. 7A). Results
show that Stat3b consistently inhibited Src-induced focus for-
mation by 50% with small amounts (2 mg) of Stat3b expression
vector, with greater than 80% inhibition observed in cotrans-
fections with larger amounts (20 mg) of Stat3b expression
vector. As a control, cotransfection of empty vector alone did
not significantly affect focus formation by v-Src, whereas ex-
pression of Stat3b alone resulted in levels of focus formation
comparable to the background of spontaneous transformation.
For comparison with v-Src, the effect of Stat3b overexpression
on focus formation induced by the activated c-H-Ras oncopro-
tein, which does not activate Stat3 signaling (14), was also
examined. Stat3b overexpression had either no effect (at 2 mg
of vector) or much-less-pronounced effects (at 20 mg of vec-
tor) on Ras-induced transformation compared to Src-induced
transformation (compare Fig. 7A and B). These results indi-
cate that Stat3b inhibits transformation by Src to a significantly
greater extent than it does transformation by Ras.
Cell lines stably overexpressing Stat3b are resistant to Src
transformation. To confirm the results obtained in the cotrans-
fection experiments described above, and to exclude a possible
toxic effect of Stat3b overexpression on cell viability, a different
approach was taken with cell lines stably overexpressing Stat3b.
Following transfection with Stat3b expression vector, G418-
resistant colonies were selected, expanded, and further charac-
terized. Western blot analysis with antibodies directed against
the N-terminal portion of Stat3 identified three independent
clones that stably overexpressed Stat3b compared to control
NIH 3T3 cells (Fig. 8A). Transient transfection of these cells
FIG. 3. Stat3b disrupts, and Stat3 augments, Src-induced gene expression.
NIH 3T3 cells were transiently transfected and luciferase reporter activities were
assayed as described for Fig. 1. (A) Cells were transfected with the Stat3 re-
porter, pLucTKS3, and v-Src vector together with increasing concentrations of
vector encoding Stat3b. (B) Cells were transfected with pLucTKS3 reporter and
vectors encoding v-Src, full-length Stat3 (pVRStat3), or both. Values are means
plus standard deviations of at least three independent experiments, each per-
formed in triplicate and normalized to b-Gal activity.
FIG. 4. Stat3b specifically blocks Stat3 but not Ras or Raf-1 signaling in-
duced by v-Src. NIH 3T3 cells were transiently transfected and luciferase re-
porter activities were assayed as described for Fig. 1. (A) Cells were transfected
with pLucCRP reporter together with or without vectors encoding v-Src, Stat3b,
or both. (B) Cells were transfected with pLucSRE reporter together with v-Src
in the presence or absence of vectors encoding Stat3b, N17-Ras, or NT-Raf. The
N17-Ras and NT-Raf proteins are dominant negative mutants of c-H-Ras and Raf-
1, respectively. Values are means plus standard deviations of at least three indepen-
dent transfections, each performed in triplicate and normalized to b-Gal activity.
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with pLucTKS3 reporter together with v-Src vector confirmed
that Stat3-mediated signaling was abrogated by Stat3b over-
expression, while Stat3-independent signaling leading to
pLucSRE induction was not affected (Fig. 8B). In agreement
with the results presented in Fig. 2 to 4, these results indicate
that Stat3b specifically disrupts Stat3 signaling without impair-
ing v-Src function or other signaling pathways. These findings
further demonstrate that cells which stably overexpress Stat3b
and are deficient in Stat3-mediated signaling remain viable and
proliferate. To assess whether these Stat3b overexpressing clones
could be transformed by Src, focus formation assays were per-
formed following transfection with v-Src expression vector.
Results presented in Fig. 9 show that all three Stat3b-over-
expressing clones were refractory to Src-induced cell trans-
formation, with up to 90% inhibition of focus formation.
Together, the data shown in Fig. 7 to 9 demonstrate that
overexpression of Stat3b blocks cell transformation by v-Src,
presumably by disrupting Stat3-dependent regulation of the
cellular gene expression that is required for v-Src transfor-
mation.
DISCUSSION
The initial discoveries of STAT proteins as mediators of
intracellular signaling in response to cytokines and growth
factors have launched an intensive investigation into the di-
verse biological functions of STATs (12, 16, 21). Activation of
STAT signaling pathways, including Stat3, has been increas-
ingly associated with cell transformation and human cancer (7,
11, 14, 15, 24, 25, 32, 42, 43, 47, 49). Cell transformation by
v-Src is an ideal system for evaluating the role of Stat3 in
oncogenesis because Stat3 is constitutively activated in mam-
malian fibroblasts stably transformed by v-Src (7, 47), suggest-
ing a requirement for continuous signaling through Stat3 in
order to maintain transformation. Moreover, we have deter-
mined that Stat3 is the predominant STAT family member
activated in Src-transformed NIH 3T3 cells, with very little or
no detectable activation of other STATs (14, 47), simplifying
the analysis of Stat3’s role without the complexity of signaling
by other STAT family members. To evaluate the role of Stat3
signaling in Src transformation, it was important to first estab-
FIG. 5. Specificity of promoter elements for STAT signaling induced by v-Src
or IFN-g. NIH 3T3 cells were transiently transfected and luciferase reporter
activities were assayed as described for Fig. 1. (A) Cells were transfected with
pLucTKSIE together with expression vectors for v-Src, Stat3b, or both. Trans-
fectants with reporter alone or reporter and Stat3b vector were treated with
IFN-g for 5 h prior to harvest of cells. (B) Cells were transfected with the
indicated reporters in the presence or absence of v-Src expression vector. Cells
transfected with reporter alone were treated with IFN-g for 5 h prior to harvest.
Values are means plus standard deviations of at least three independent exper-
iments, each performed in triplicate and normalized to b-Gal activity.
FIG. 6. Induction of SIE binding activity by v-Src in transfected cells. Nuclear
extracts were prepared from transiently transfected NIH 3T3 cells, and volumes
containing equal amounts of total protein were subjected to EMSA by using
32P-labeled hSIE. (A) Cells were transfected with v-Src vector alone (NIH 3T3)
or v-Src vector together with either Stat3 or Stat3b vector, as indicated. Lanes 7
to 10 are 1:10 dilutions of the samples loaded in lanes 3 to 6, respectively.
Competitions of endogenous hSIE binding activity present in nuclear extracts of
NIH 3T3 cells transfected with v-Src vector alone (lanes 12 and 13) were per-
formed with a 100-fold molar excess of unlabeled hSIE or the unrelated c-fos
intragenic regulatory element (FIRE) oligonucleotides. Supershifts (lanes 14 and
15) were performed with antibodies recognizing either amino acids 688 to 710 of
Stat1 (aST1) or amino acids 750 to 769 of full-length Stat3 (aST3). (B) Nuclear
extracts from cells transfected with v-Src vector plus Stat3 and/or Stat3b vector
were subjected to EMSA, with competitions and supershifts performed as de-
scribed for panel A. ST3, ST3b, and ST3/ST3b indicate migration of complexes
containing Stat3 homodimers, Stat3b homodimers, and Stat3-Stat3b hetero-
dimers, respectively. Asterisks indicate positions of supershifted complexes.
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lish that activation of Stat3 by v-Src leads to regulation of
specific gene expression which could be disrupted in a domi-
nant-negative manner by Stat3b. Our results demonstrate that
activation of endogenous cellular Stat3 by the v-Src oncopro-
tein induces Stat3-mediated gene regulation that is specifically
abrogated by overexpression of Stat3b in NIH 3T3 cells. The
findings reported here establish the transcriptional potential of
the frequently observed activation of Stat3 in transformed cells
and provide evidence that this Stat3 signaling participates in
oncogenesis. Because Stat3 is a constitutively activated tran-
scription factor in the context of oncogenesis, these findings
further imply a permanent alteration in the genetic program
that contributes to oncogenesis of transformed cells harboring
activated Stat3.
While the precise mechanism of Stat3 activation by Src is not
completely defined, it has been shown that v-Src associates in
a complex with Stat3 (7), consistent with the possibility that
v-Src directly phosphorylates and activates Stat3. Other studies
have provided evidence that JAK family kinases are constitu-
tively activated in Src-transformed fibroblasts, suggesting that
v-Src may indirectly activate Stat3 through JAKs (6). These
two mechanisms are not mutually exclusive, and it is possible
that both contribute to activation of Stat3 signaling by v-Src. In
addition, we analyzed the interactions of Stat3 and Stat3b with
each other to explore the mechanism by which overexpression
of Stat3b could disrupt Stat3 signaling activated by Src. We
detected DNA-binding activity by overexpressed Stat3b ho-
modimers and Stat3-Stat3b heterodimers in nuclear extracts
prepared from cells transiently transfected with v-Src, consis-
tent with two possible mechanisms. One potential mechanism
is the occupation of Stat3 binding sites by Stat3b homodimers,
thereby titrating sites available for binding Stat3 homodimers.
On the other hand, another possibility is that Stat3b could
form heterodimers with Stat3 which may be transactivation
deficient. Either or both of these mechanisms may contribute
to the disruption of Stat3 signaling in NIH 3T3 cells under
conditions in which Stat3 is constitutively activated by v-Src.
At the amino acid level, Stat3b is identical to full-length
Stat3 for most of the protein but diverges at the carboxyl
terminus with an internal deletion in the transactivation do-
main (5, 34). In the case of mouse Stat3, 55 amino acids are
replaced by 7 different residues in Stat3b (34), whereas in the
case of human Stat3, 17 amino acids are replaced by 7 different
residues in Stat3b (5). Significantly, Stat3b retains the critical
tyrosine residue at position 705 (Tyr-704 in human Stat3b),
the phosphorylation of which is required for dimerization and
DNA binding, but lacks the serine residue at position 727 (Ser-
FIG. 7. Cotransfection of Stat3b vector blocks transformation of NIH 3T3
cells induced by Src. (A) Cells were transfected with carrier DNA alone (con-
trol), with v-Src vector (200 ng) in the presence or absence of Stat3b vector (2 mg
or 20 mg, as indicated) or empty vector, or with Stat3b vector (20 mg) alone. (B)
Cells were transfected as described for panel A, except that activated c-H-Ras
vector was used instead of v-Src vector. At least three independent sets of
transfections were analyzed for Src and Ras focus formation assays. Values are
means plus standard deviations of transfections from each experiment; percent
focus formation is relative to that induced by Src or Ras alone (100%) within
each of the independent sets of experiments.
FIG. 8. Characterization of NIH 3T3 cell lines stably overexpressing Stat3b.
(A) Western blot analysis of whole-cell lysates prepared from three independent
NIH 3T3 cell lines stably overexpressing Stat3b. Lanes 1 to 4 were probed with
antibodies against the N-terminal portion of Stat3 which recognize both full-
length Stat3 and Stat3b. Lanes 5 to 8 were probed with antibodies to the Stat3
C terminus which recognize full-length Stat3 but not Stat3b. (B) Clone Stat3b10
was transiently transfected with either pLucSRE or pLucTKS3 reporter in the
presence or absence of vector encoding v-Src, as indicated. Values for luciferase
activity are means plus standard deviations of at least two independent transfec-
tions, each performed in triplicate. For each transfection, luciferase activity was
normalized to transfection efficiency by using b-Gal activity as an internal con-
trol.
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726 in human Stat3b). Phosphorylation of Ser-727 in full-length
Stat3 is not required for DNA binding (44), although it is
required for efficient transcriptional activation (45). However,
apparently conflicting reports in the literature regarding the
transactivation potential of Stat3b underscore the complexity
of STAT signal transduction pathways. While an earlier report
showed that coexpression of mouse Stat3b together with c-Jun
transactivates an AP-1-dependent promoter (34), recent evi-
dence demonstrates that mouse Stat3b acts as a transactivator
or dominant negative modulator of transcription in a cell-type-
specific manner (33). Although the basis for the variable trans-
activation potentials of Stat3b is unknown, it may involve in-
teractions of Stat3b with other cell-type-specific transcription
factors or coactivators. It is also possible that the structural
differences between mouse and human Stat3b in the C-termi-
nal portion or elsewhere account for the different transactiva-
tion potentials that have been observed (5, 34).
Despite being one of the most well characterized oncopro-
teins, the molecular mechanisms by which v-Src subverts nor-
mal cellular signaling pathways and transforms cells are not
fully defined (1, 38). The present data demonstrate that acti-
vation of Stat3 signaling is required for cell transformation by
the v-Src oncoprotein, suggesting that constitutive activation of
Stat3 is one of the cellular signaling pathways that participates
in maintenance of transformation by v-Src. Given the myriad
changes that accompany cell transformation (18), it is probable
that activation of Stat3 signaling is not sufficient by itself to
induce cell transformation and that other signaling pathways
are also required for transformation by v-Src. At the same
time, it is unlikely that Stat3 is involved in transformation by all
oncoproteins, since cell transformation mediated by activated
c-H-Ras was not significantly inhibited by coexpression of
Stat3b. In addition, because we have been able to generate
stable cell lines overexpressing Stat3b, these results demon-
strate that enforced overexpression of Stat3b does not severely
impair normal cell function or have toxic effects on cell viabil-
ity. Using a panel of various Stat3 dominant negative mutants
and different assays of cell transformation, Bromberg et al.
have arrived independently at similar conclusions (3). To-
gether, these findings provide the first direct evidence that, in
addition to their signaling functions in normal cells, STATs
also participate in oncogenesis. Because activation of Stat3 is
associated with human tumors, including breast carcinomas
and various lymphoid malignancies (14, 15, 32, 42, 43, 49), our
findings further suggest an important role for Stat3 signaling in
the development of these cancers.
The biological mechanism by which Stat3 contributes to
oncogenesis remains to be determined. We speculate that
Stat3 signaling may contribute to transformation induced by
v-Src in NIH 3T3 cells through one of two likely biological
mechanisms. One possible mechanism is that constitutive ac-
tivation of Stat3 signaling may directly stimulate cell prolifer-
ation. This possibility is consistent with the finding that numer-
ous growth factors, such as platelet-derived growth factor and
epidermal growth factor, activate signaling by STATs, includ-
ing Stat3 (22, 31, 40, 50). In addition, gene knockout studies
have demonstrated a requirement for Stat4 and Stat6 signaling
in mitogenic responses to cytokine stimulation of immune cells
(19, 20). Alternatively, Stat3 may contribute to cell transfor-
mation by preventing apoptosis, thereby indirectly increasing
cell numbers. This possibility is supported by the finding that
activation of Stat3 is required for the anti-apoptosis response
to IL-6 stimulation in a murine myeloid cell line (13). Since
Stat3 signaling is implicated in control of cell differentiation,
proliferation, and apoptosis (10, 13, 27, 39), the biological
consequences of constitutive Stat3 activation are likely to be
complex and dependent on the specific cell type. Nevertheless,
the demonstration that Stat3 is one of the critical signaling
pathways required for cell transformation by v-Src implies the
existence of Stat3-regulated genes that participate in oncogen-
esis. Thus, identification and characterization of the nuclear
genes regulated by Stat3 should provide new insights into the
specific events leading to the loss of normal cell growth control
and the process of malignant transformation.
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